KSP, McLaren's Specialty Pharmacy, Recognized as a Leader in Performance Measurement for Second Consecutive Year

The URAC awards KSP as a top-performing specialty pharmacy committed to making key contributions to advance performance measurement within accreditation programs

DETROIT, June 26, 2024 /PRNewswire/ -- The Utilization Review Accreditation Commission (URAC) has once again awarded KSP, McLaren's Specialty Pharmacy, as a 2023 Pioneer in URAC's Leaders in Performance Measurement (LPM) recognition program. As a URAC-accredited organization, this distinction shows that KSP continues to demonstrate a commitment to improving health care quality and well-being through performance measurement.

As a specialty pharmacy, KSP provides needed medications and therapeutics at an affordable cost for patients with complex diseases or whose care requires high-cost treatments. Physicians utilize KSP to fill prescriptions to treat cancer, HIV, gastrointestinal diseases, neurological disorders, and more at an affordable cost to the patient. Being a Pioneer in Performance Management means KSP is going above mandatory reporting requirements, which helps to provide insights into cutting-edge measurement concepts.

"We're elated to be announced as a Pioneer for the second year in a row. KSP is committed to the patients we serve. In the work that we do to help their health care needs, we want to ensure we are making a difference," said Stephen Kaurala, PharmD, MBA, BCOP, KSP pharmacy manager. "Our team does a tremendous job at ensuring a seamless continuum of care through each patient's therapy journey."

Within the URAC's LPM programs, this award recognizes KSP as a leader among the Specialty Pharmacy programs. When evaluating specialty pharmacies, the URAC's Quality, Research and Measurement Team considered data submitted in 2023, which was collected between January 1 through December 31, 2022. Along with the data, specialty pharmacies must meet specific criteria, including holding a current and full URAC accreditation status, submitting measures on time for the reporting period, and participating in key activities beyond mandatory requirements. This is KSP's second time receiving LPM recognition.

"As McLaren's preferred specialty pharmacy, KSP fills the need for many patients throughout Michigan who need unique medications not found at their local pharmacy," said Brian Gamble, president of the Karmanos Cancer Hospital and Karmanos Cancer Network. "KSP staff has worked diligently to improve the health and well-being of the patients McLaren serves. I am very proud of this dedication to quality and service, KSP's hard work on exceeding accreditation standards, and being named a Pioneer by URAC."

KSP achieved URAC Specialty Pharmacy reaccreditation in August 2023, after first receiving the achievement in 2020. For full accreditation, the organization is evaluated based on risk management standards, operations and infrastructure, performance monitoring and improvement, consumer protection and empowerment, pharmacy operations, medication distribution, patient service and communication, patient management, and reporting performance measures to the URAC.

As an extension of the Barbara Ann Karmanos Cancer Institute, part of McLaren Health Care, KSP has grown to assist with the specialty needs of all McLaren patients in Michigan, Ohio and Indiana. Learn more about KSP at ksppharmacy.org.

About McLaren Health Care
McLaren Health Care, headquartered in Grand Blanc, Michigan, is a $6.6 billion, fully integrated health care delivery system committed to quality, evidence-based patient care and cost efficiency. The McLaren system includes 14 hospitals in Michigan, ambulatory surgery centers, imaging centers, a 490-member employed primary and specialty care physician network, commercial and Medicaid HMOs covering more than 732,838 lives in Michigan and Indiana, home health, infusion and hospice providers, pharmacy services, a clinical laboratory network and a wholly owned medical malpractice insurance company. McLaren operates Michigan's largest network of cancer centers and providers, anchored by the Karmanos Cancer Institute, one of only 53 National Cancer Institute-designated comprehensive cancer centers in the U.S. McLaren has 28,000 full-, part-time and contracted employees and more than 113,000 network providers throughout Michigan, Indiana and Ohio. Learn more at mclaren.org.

About the Barbara Ann Karmanos Cancer Institute
Karmanos Cancer Institute is a leader in transformative cancer care, research and education through courage, commitment and compassion. The Karmanos vision is a world free of cancer. As part of McLaren Health Care, Karmanos is the largest provider of cancer care and research in Michigan. For more than 75 years, the administrative and research headquarters, along with the premier specialty cancer hospital, have been located in downtown Detroit. With 16 network sites, Karmanos delivers world-renowned care and access to clinical trials throughout Michigan and northern Ohio. The National Cancer Institute recognizes Karmanos as one of the best cancer centers in the nation with a comprehensive cancer center designation. Its academic partnership with the Wayne State University School of Medicine provides the framework for cancer research and education – defining new standards of care and improving survivorship. For more information, call 1-800-KARMANOS (800-527-6266) or visit www.karmanos.org. Follow Karmanos on Facebook, Twitter, LinkedIn and YouTube.

SOURCE Karmanos Cancer Institute